Rivelli v. Hemm

CourtCalifornia Court of Appeal
DecidedAugust 2, 2021
DocketH046878
StatusPublished

This text of Rivelli v. Hemm (Rivelli v. Hemm) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rivelli v. Hemm, (Cal. Ct. App. 2021).

Opinion

Filed 8/2/21

CERTIFIED FOR PUBLICATION

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SIXTH APPELLATE DISTRICT

PATRICK J. RIVELLI et al., H046878 (Santa Clara County Plaintiffs and Appellants, Super. Ct. No. 18CV326785)

v.

FRANK HEMM et al.,

Defendants and Respondents.

In this appeal, we decide whether a Swiss company and its executive vice president, a Swiss citizen and resident, are subject to suit in California court for claims related to the purchase by the Swiss company of shares of a privately-held California corporation. The trial court granted the Swiss defendants’ motions to quash service of summons for lack of personal jurisdiction. For the reasons explained below, we affirm the order. I. FACTS AND PROCEDURAL BACKGROUND A. Facts 1 Appellants Patrick Rivelli (Rivelli) and Pinecroft Ventures, LLC (Pinecroft) are Series A preferred shareholders in Rodo Medical, Inc. (Rodo), a medical device company

1 These facts are taken from the pleadings and evidence submitted in support of and in opposition to the motions to quash service of summons, including sworn declarations, jurisdictional discovery responses, and the agreements comprising the transaction underlying the dispute, which have been filed under seal. Except where noted, the facts presented are undisputed. in the field of dental implants. Rivelli is a resident of Massachusetts, and Pinecroft is a Nevada limited liability company with its primary place of business in Incline Village, Nevada. Rodo is a California corporation with its primary place of business in San Jose, California. Rivelli and Pinecroft (together, appellants) filed this lawsuit against Rodo and certain Rodo officers and directors (collectively, defendants). 2 Only two of these defendants—Institut Straumann AG and Frank Hemm (together, respondents or Swiss defendants)—are party to this appeal. Institut Straumann AG (Straumann) is a foreign corporation with its primary place of business in Basel, Switzerland. Straumann, like Rodo, manufactures and distributes dental supplies and equipment, specializing in tooth replacement and restoration. Straumann holds a minority equity ownership interest in Rodo. Frank Hemm (Hemm) is a citizen and resident of Switzerland. Hemm is a corporate officer of Straumann and, at all times relevant to this appeal, was a Rodo director. Appellants Rivelli and Pinecroft acquired their shares in Rodo in 2010, shortly after Rodo was founded. They were among several investors who bought Series A Preferred Stock (Series A) in Rodo based on various representations by the company, including that Series A shareholders would retain a liquidation preference over common stockholders, would have their own representative on Rodo’s board of directors, would have certain preemption and anti-dilution rights, and that the Series A shares would be non-redeemable. In 2014, Straumann—the Swiss company—acquired a 12 percent minority interest in Rodo. Hemm, an executive vice president of Straumann, joined Rodo’s board of

2 The defendants named in the operative first amended complaint are corporate defendants Rodo Medical, Inc. and Institut Straumann AG, and individual or director defendants Frank Hemm, Young Seo, Amir Abolfathi, Greg Garfield, Kevin Mosher, and Mike Winzeler. 2 directors in April 2016. 3 Hemm served as a Rodo director, and at times as a member of the Rodo board’s compensation committee, until May 2018. In late 2016, Rodo received approval from the United States Food & Drug Administration (FDA) to sell its dental device. Rodo’s management began to negotiate with Straumann the terms of a stock purchase agreement, referred to by the parties as the “Straumann Transaction” (hereafter, “the transaction”). The transaction ultimately increased Straumann’s equity interest in Rodo from 12 percent to 30 percent. From September 2016 through December 2016, Hemm participated on behalf of Straumann in Rodo board discussions concerning the transaction, but Hemm asserts he did not participate in the Rodo board’s decisions or in the vote approving the transaction. Rodo’s board meetings were conducted in California. Hemm attended Rodo board meetings on at least 13 occasions between September 2016 and April 2018, primarily by phone and at least once in person. According to Hemm, his role as a Rodo director during that time “centered on providing insight to Rodo regarding the suitability of its product portfolio and its commercialization strategy (sales channels, pricing, regulatory requirements) in and outside the United States.” According to appellant Rivelli, Hemm traveled to California to attend board meetings in person in September 2016 and December 2016 and did not fully recuse himself from negotiations or discussions related to the transaction but instead attempted to dissuade the board from considering deals with other investors. In March 2017, Rodo’s board approved the transaction and authorized Rodo’s management to solicit shareholder approval of the transaction. An information statement 3 Although Hemm’s verified declaration states that he served as a member of the Rodo board of directors from approximately April 2017 until May 7, 2018, it is apparent from respondents’ briefing on appeal, as well as from other parts of the record (including Hemm’s responses to plaintiff’s special interrogatories re: personal jurisdiction), that Hemm served on the Rodo board of directors from approximately April 2016 until May 7, 2018, while Institut Straumann executive Guillaume Dannelliot served on the Rodo board of directors from approximately April 2017 until May 7, 2018. 3 detailing the transaction, its risks and benefits, and the consequences of its approval was sent to Rodo shareholders, requesting their written consent. Hemm did not participate in the drafting of the information statement. For those shareholders holding shares of preferred stock, the information statement further asked them to sign amended and restated voting, investor rights, and co-sale agreements. The transaction closed on April 13, 2017, at the Palo Alto, California offices of Rodo’s legal counsel. The transaction is memorialized in a set of at least eight documents, including an amended and restated investor rights agreement, an amended and restated voting agreement, a stock purchase and exchange agreement, an exclusive distribution agreement, a right of first refusal agreement, a revolving line of credit term sheet, and an indemnification agreement. 4 Hemm signed the agreements on behalf of Straumann, as did Straumann’s general counsel, Dr. Andreas Meier. Through the transaction, Straumann gained an additional seat on the Rodo board of directors (for a total of two seats), became Rodo’s exclusive worldwide distributor (excepting the United States, Canada, Hong Kong and South Korea) under an exclusive distributorship and license agreement, agreed to establish a revolving $5 million line of credit between Straumann and Rodo (if requested by Rodo and subject to negotiation of a separate credit agreement), and gained “considerable influence over the long-term viability of” Rodo, as explained in the information statement presented to Rodo’s shareholders. The transaction limited Rodo’s control of acquisition and financing for four to six years and rendered shares held by shareholders other than Straumann, including those of the Series A shareholders, subject to redemption.

4 The agreements that together comprise the transaction are part of the sealed record, as is the information statement furnished by Rodo for the purpose of summarizing the proposed transaction and soliciting the written consent of Rodo’s shareholders to approve the transaction and adopt the agreements. In accordance with their sealed status, we have limited our references in this opinion to those terms of the agreements described by the parties in their briefs, which have not been filed under seal.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
World-Wide Volkswagen Corp. v. Woodson
444 U.S. 286 (Supreme Court, 1980)
Keeton v. Hustler Magazine, Inc.
465 U.S. 770 (Supreme Court, 1984)
Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Foreman & Clark Corp. v. Fallon
479 P.2d 362 (California Supreme Court, 1971)
Vons Companies, Inc. v. Seabest Foods, Inc.
926 P.2d 1085 (California Supreme Court, 1996)
Ziller Electronics Lab GmbH v. Superior Court
206 Cal. App. 3d 1222 (California Court of Appeal, 1988)
Taylor-Rush v. Multitech Corp.
217 Cal. App. 3d 103 (California Court of Appeal, 1990)
Great-West Life Assur. v. Guar. Co. of N. America
205 Cal. App. 3d 199 (California Court of Appeal, 1988)
F. HOFFMAN-LA ROCHE, LTD. v. Superior Court
30 Cal. Rptr. 3d 407 (California Court of Appeal, 2005)
Sonora Diamond Corp. v. Superior Court
99 Cal. Rptr. 2d 824 (California Court of Appeal, 2000)
Epic Communications, Inc. v. Richwave Technology, Inc.
179 Cal. App. 4th 314 (California Court of Appeal, 2009)
Edmunds v. Superior Court
24 Cal. App. 4th 221 (California Court of Appeal, 1994)
Checker Motors Corp. v. Superior Court
13 Cal. App. 4th 1007 (California Court of Appeal, 1993)
Jewish Defense Organization, Inc. v. Superior Court
85 Cal. Rptr. 2d 611 (California Court of Appeal, 1999)
Snowney v. Harrah's Entertainment, Inc.
112 P.3d 28 (California Supreme Court, 2005)
Pavlovich v. Superior Court
58 P.3d 2 (California Supreme Court, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
Rivelli v. Hemm, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rivelli-v-hemm-calctapp-2021.